Chief Regulatory Officer
O11 biomedical
O11 Biomedical develops RESPILIQ™, a therapeutic solution targeting respiratory diseases through advanced biomedical technology derived from research at RWTH Aachen University. The company aims to improve patient outcomes by providing effective treatments for common respiratory conditions.
- Biotechnology
- Healthcare Technology
Updated 23 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Problem
Respiratory diseases pose a significant global health challenge, impacting millions of individuals and resulting in substantial healthcare costs. Current treatment options often provide limited relief and may not address the underlying causes of these conditions. There is a need for more effective and targeted therapies to improve patient outcomes and quality of life.
Solution
O11 Biomedical is developing RESPILIQ™, a therapeutic solution designed to address respiratory diseases using advanced biomedical technology. This technology, originating from research at RWTH Aachen University, aims to provide more effective treatments for common respiratory conditions. RESPILIQ™ offers a novel approach to managing these diseases, potentially leading to improved patient outcomes and a better quality of life for those affected. The company focuses on translating cutting-edge research into practical therapeutic applications.
Target Audience
The primary target audience includes individuals suffering from respiratory diseases, as well as healthcare professionals seeking more effective treatment options.
Features
- Advanced biomedical technology derived from RWTH Aachen University research
- Targeted therapeutic solution for respiratory diseases
- Aims to improve patient outcomes for common respiratory conditions